ArticleCureus2024
Comparing Two Vancomycin Loading Dose Regimens in Patients With Obesity: A Single-Center Prospective Clinical Trial.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity can significantly influence the pharmacokinetics of several medications, including vancomycin. Consequently, specialized dosing strategies may be required to ensure efficacy and safety in patients with obesity (PwO) requiring treatment with vancomycin. This single-center, prospective study evaluated two vancomycin loading dose regimens in PwO, comparing serum vancomycin concentrations, adverse events, and the impact on renal function.
methodsAdult patients weighing over 100 kg were randomized into two study groups. A 20 mg/kg loading dose of vancomycin was administered to both groups, with one group restricted to a maximum dose of 2000 mg (n=33) and the other group receiving up to 4000 mg (n=34).
resultsPatients receiving the 4000 mg maximal dose achieved significantly higher median vancomycin concentrations at the initial trough (9.1 mg/L vs. 11.3 mg/L, p=0.0497), mean concentrations at the 7.5-hour interval trough (14.4 mg/L vs. 17.1 mg/L, p=0.0151), and mean concentrations at the post-load peak (23.9 mg/L vs. 30.9 mg/L, p=0.0023), without a corresponding increase in adverse renal outcomes, hospital length of stay, or mortality as compared with the 2000 mg maximum dose group.
conclusionsThe study's findings demonstrate that higher vancomycin doses in PwO are safely tolerated and do not result in short-term adverse effects on renal function. This study helps us better understand vancomycin pharmacotherapy in PwO, supporting the need for further research to refine dosing guidelines for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.